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Abstract
Background: The prevalence of allergic diseases in infants, whose parents and siblings do not have allergy, is
approximately 10 % and reaches 20–30 % in those with an allergic first-degree relative. Intestinal microbiota may
modulate immunologic and inflammatory systemic responses and, thus, influence development of sensitization and
allergy. Prebiotics – non-digestible oligosaccharides that stimulate growth of probiotic bacteria – have been
reported to modulate immune responses and their supplementation has been proposed as a preventive
intervention.
Objective: The World Allergy Organization (WAO) convened a guideline panel to develop evidence-based
recommendations about the use of prebiotics in the prevention of allergy.
Methods: The WAO guideline panel identified the most relevant clinical questions about the use of prebiotics for
the prevention of allergy. We performed a systematic review of randomized controlled trials of prebiotics, and
reviewed the evidence about patient values and preferences, and resource requirements (up to January 2015, with
an update on July 29, 2015). We followed the Grading of Recommendations Assessment, Development and
Evaluation (GRADE) approach to develop recommendations.
Results: Based on GRADE evidence to decision frameworks, the WAO guideline panel suggests using prebiotic
supplementation in not-exclusively breastfed infants and not using prebiotic supplementation in exclusively
breastfed infants. Both recommendations are conditional and based on very low certainty of the evidence. We
found no experimental or observational study of prebiotic supplementation in pregnant women or in breastfeeding
mothers. Thus, the WAO guideline panel chose not to provide a recommendation about prebiotic supplementation
in pregnancy or during breastfeeding, at this time.
Conclusions: WAO recommendations about prebiotic supplementation for the prevention of allergy are intended
to support parents, clinicians and other health care professionals in their decisions whether or not to use prebiotics
for the purpose of preventing allergies in healthy, term infants.
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Executive summary
The purpose of this document is to provide evidence-
based recommendations about the use of prebiotic sup-
plements for the primary prevention of allergies.
Allergic diseases have a prevalence of 10 % in infants
without an allergic parent or sibling, and 20 – 30 % in
those with allergy in their relatives. It has been suggested
that intestinal microbiota may modulate immunologic
and inflammatory systemic responses and, thus, influ-
ence the development of sensitization and allergy. Prebi-
otics are non-digestible food components that have been
advocated as preventive interventions for allergic dis-
eases by promoting a balanced growth of the intestinal
microbiota.
Methodology
The methods used to develop clinical recommenda-
tions in this document follow the GRADE approach
[1, 2]. The Guideline panel included clinicians and re-
searchers in the field of allergy (allergists), pediatri-
cians, primary care physicians, and methodologists.
Potential conflicts of interests were managed as sug-
gested by the World Health Organization.
The guideline panel developed and graded the rec-
ommendations and assessed the quality of the sup-
porting evidence following the GRADE approach. The
quality of evidence (also called confidence in the
available estimates of health effects or certainty in the
evidence) is categorized as: high, moderate, low or
very low based on consideration of risk of bias, indir-
ectness of evidence, inconsistency and imprecision of
effect estimates. Low and very low quality evidence
indicates that the estimated effects of interventions
are very uncertain.
Interpretation of strong and conditional
recommendations
The strength of a recommendation is expressed as either
strong (“guideline panel recommends…”), or conditional
(“guideline panel suggests…”) and has the following
interpretation:
Strong recommendation
▪ For patients: most individuals in this situation would
want the recommended course of action, and only a
small proportion would not.
▪ For clinicians: most individuals should receive the
intervention. Adherence to this recommendation
according to the guideline could be used as a
quality criterion or performance indicator. Formal
decision aids are not likely to be needed to help
individuals make decisions consistent with their
values and preferences.
▪ For policy makers: the recommendation can be
adopted as policy in most situations.
Conditional recommendation
▪ For patients: the majority of individuals in this
situation would want the suggested course of action,
but many would not.
▪ For clinicians: recognize that different choices will be
appropriate for individual patients and that you must
help each patient arrive at a management decision
consistent with his or her values and preferences.
Decision aids may be useful in helping individuals to
make decisions consistent with their values and
preferences.
▪ For policy makers: policy-making will require substan-
tial debate and involvement of various stakeholders.
How to use these guidelines
The GLAD-P guidelines about the use of prebiotics
provide the basis for rational, informed decisions for
clinicians, parents and other decision makers. Clini-
cians, parents and other caregivers, third-party
payers, institutional review committees, other
stakeholders, or the courts should never view these
recommendations as dictates. No recommendation
can take into account all of the often-compelling
unique individual circumstances but provides guid-
ance. However, no one charged with evaluating
health care professional’s actions should attempt to
apply the recommendations from these guidelines by
rote or in a blanket fashion.
Note: statements about the underlying values and pref-
erences as well as qualifying remarks accompanying each
recommendation as well as the evidence to decision
frameworks are its integral parts and serve to facilitate
more accurate interpretation; they should never be omit-
ted when quoting or translating recommendations from
these guidelines.
Recommendations
Question 1. Should prebiotics be used in pregnant
women?
The WAO guideline panel chose to provide no recom-
mendation at this time owing to lack of experimental
and observational studies in which prebiotic supple-
ments would be used in pregnant women.
Question 2. Should prebiotics be used in breast-
feeding mothers?
The WAO guideline panel chose to provide no recom-
mendation at this time owing to lack of experimental
and observational studies in which prebiotic supple-
ments would be used in breastfeeding mothers.
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Question 3. Should prebiotics be used in healthy
infants?
Recommendation: The WAO guideline panel sug-
gests prebiotic supplementation in not-exclusively
breastfed infants, both at high and at low risk for devel-
oping allergy (conditional recommendation, very low
certainty of evidence).
The WAO guideline panel suggests that clinicians and
parents do not use prebiotic supplementation in exclu-
sively breastfed infants (conditional recommendation,
very low certainty of the evidence).
Values and preferences
The recommendation to use prebiotics in not-
exclusively breastfed infants places a relatively higher
value on possible prevention of allergies and a relatively
lower value on additional cost of prebiotic supplementa-
tion. The recommendation not to use prebiotics in ex-
clusively breastfed infants places a relatively higher value
on avoiding additional cost and burden of implementa-
tion of such supplementation and a relatively lower
value on uncertain effect on prevention of allergies (cur-
rently there are also no studies of health effects of prebi-
otics in exclusively breastfed infants and the panel found
it not justified to extrapolate from the effects observed
in non-exclusively breastfed infants).
Explanations and other considerations
These recommendations should not lead to any change
in the practice or promotion of breastfeeding in infants.
Formulas supplemented with prebiotics should not be
considered a substitute for breast milk. Sole availability
of such formulas should not influence the decision to
breastfeed and/or the duration of breastfeeding. These
recommendations apply to otherwise healthy term in-
fants in whom prebiotics would be used with the goal of
preventing allergies.
Scope and purpose
The purpose of this document is to provide guidance on
the use of prebiotics for the primary prevention of aller-
gies. The target audience of these guidelines are general
practitioners, paediatricians, allergists, pulmonologists
and dermatologists. General internists, and other health
care professionals and health policy makers may also
benefit from these guidelines. Policy makers interested
in these guidelines include those involved in developing
local, national or international plans with the goal to re-
duce incidence of allergy and resource direct and indir-
ect costs related to allergic diseases [3]. This document
may also serve as the basis for development and imple-
mentation of locally adapted guidelines.
Background
Allergic diseases are considered a worldwide burden in
different populations. It is considered that approximately
20 % of the population will have an allergic disease at
some point in their lives [4]. The prevalence of allergic
diseases in infants depends on the allergic status of their
parents; for example, the prevalence is 20 – 30 % in
those with an atopic background in their first-degree rel-
atives, while in those without an allergic parent or sib-
ling the risk decreases to about 10 % [5].
Recent studies have provided researchers more reasons
to move their attention to the intestinal microbiota as
one of the main culprits for the rising incidence of aller-
gic disorders; its influence on sensitization and its ability
to modulate immunologic and inflammatory systemic
responses are the main reasons for this suspicion; [6] in
consequence, the “hygiene” or “microflora” hypothesis
has been proposed to explain these phenomena [7].
Prebiotics have been defined as “non-digestible food
components that beneficially affect the host by select-
ively stimulating the growth and/or activity of one or a
limited number of bacteria in the colon and thereby im-
proving host health” and later redefined as”a selectively
fermented ingredient that allows specific changes, both
in the composition and/or activity in the gastrointestinal
microbiota that confers benefits” [6, 8, 9].
The Guidelines for Atopic Disease Prevention (GLAD-
P) is a joint effort of the World Allergy Organization
(WAO) and the Department of Clinical Epidemiology &
Biostatistics at McMaster University to evaluate the
current evidence on the preventive effect of probiotics,
prebiotics, and vitamin D on allergic diseases and related
clinically important outcomes. This document provides
recommendations and the rationale for use of prebiotics.
For clarity of communication we used the following
definitions throughout the document:
 Prebiotics: “a selectively fermented ingredient that
allows specific changes, both in the composition
and/or activity in the gastrointestinal microbiota,
thus conferring benefit(s) upon host health.” [6, 8,
9]. Prebiotics most commonly used as components
of infant feeds are non-digestible carbohydrates;
mostly fructans like inulin, oligofructose, and fructo-
oligosaccharides (FOS); other prebiotics in use in-
clude isomaltooligosaccharides, soybean
oligosaccharides, gentiooligosaccharides, galacto-
oligosaccharides (GOS), and xylooligosaccharides.
These are substances primarily derived from plants
and commonly found in foods like garlic, onion and
artichoke, among others. To consider a substance a
prebiotic, this must: a) resist gastric acidity, lysis by
enzymes, and absorption in the gastrointestinal tract;
b) be fermented by intestinal microbiota; and c)
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selectively stimulate the growth and/or activity of in-
testinal bacteria potentially associated with health
and well-being [8, 9].
 High risk for allergy in a child: biological parent or
sibling with existing or history of allergic rhinitis,
asthma, eczema, or food allergy [10].
Methods
Panel composition and meetings
We followed the procedures and methodology using
the GIN-McMaster Guideline Development Checklist
(http://cebgrade.mcmaster.ca/guidecheck.html) [2] to
assemble a team of experts including allergists, paedi-
atricians, family physicians and representatives of the
general public. The guideline panel also included
methodologists who helped prepare systematic reviews
and evidence summaries following the GRADE
approach.
A face-to-face meeting was held in January 2015 coin-
ciding with the WAO Symposium in Rome, Italy. During
the meeting the guideline panel discussed specific ques-
tions, the existing research evidence and made
recommendations.
Disclosure of potential conflicts of interest
Guideline panel members disclosed all potential conflicts
of interest according to the World Health Organization
policies. The chairs (AF, RP and HJS) reviewed and re-
solved all potential conflicts of interest of panel mem-
bers (see online Additional file 1 for the list of declared
conflicts of interest for all panel members). During all
deliberations, panel members with potential conflicts of
interest recused themselves from final decisions about
recommendations.
The WAO provided meeting facilities during its Sym-
posium and financial support to perform systematic re-
views. The views and interests of the WAO as well as of
any commercial entity that provided external funding for
WAO had no influence on the final recommendations.
Formulating specific clinical questions and determining
outcomes of interest
We used the GRADEpro Guideline Development Tool
(www.gradepro.org) [11] and SurveyMonkey (survey-
monkey.com) to brainstorm and subsequently prioritize
questions related to the use of prebiotics for the preven-
tion of allergy.
The following questions were chosen to be addressed
in this document:
1. Should prebiotics vs. no prebiotics be used in
pregnant women?
2. Should prebiotics vs. no prebiotics be used in
breastfeeding women?
3. Should prebiotics vs. no prebiotics be used in
infants?
The guideline panel selected outcomes of interest for
each question following the general approach suggested
by the GRADE Working Group [1]. All outcomes were
identified a priori and the panel explicitly rated their
relative importance for decision-making using an online
software. Rating outcomes by their relative importance
can help focus attention on those outcomes that are
considered most important and help to resolve or clarify
potential disagreements.
Evidence review and development of clinical
recommendations
Evidence summaries for each question were prepared by
the methodologists (JB, CCG, JJYN, GPM, YZ, and HJS)
following the GRADE approach and using the Guideline
Development Tool (www.gradepro.org). All guideline
panel members reviewed the summaries of evidence and
made corrections when appropriate. We based the evi-
dence summaries on a systematic review of the literature
performed specifically for these guidelines (Reference. in
preparation). An updated search strategy (presented in
the online Additional file 2) was performed on July 29,
2015 that did not provide any additional studies. We
followed the methods outlined in the Cochrane Hand-
book for Systematic Reviews of Interventions (hand-
book.cochrane.org) and assessed the risk of bias at the
outcome level using the Cochrane Collaboration’s risk of
bias tool [12]. Subsequently, we assessed the quality of
the body of evidence (also known as certainty of evi-
dence or confidence in the estimated effects) for each of
the outcomes of interest following the GRADE approach
based on the following criteria: risk of bias, precision,
consistency and magnitude of the estimates of effects,
directness of the evidence, risk of publications bias, pres-
ence of dose–effect relationship, and an assessment of
the effect of residual, opposing confounding. Quality
(also called certainty) was categorized into 4 levels ran-
ging from very low to high. In addition, we searched for
evidence about values and preferences and cost of pre-
biotic supplementation. We prepared the evidence-to-
decision tables based on the estimates of the health ef-
fects, values and preferences and resource use.
During the meeting the guideline panel developed rec-
ommendations based on the evidence summaries and
the evidence-to-decision frameworks [13–15]. For each
recommendation, the guideline panel considered and
agreed on the following: the quality of the evidence, the
health balance of benefits and harms of the compared
management options and the assumptions about the
values and preferences associated with the decision. The
guideline panel also explicitly took into account the
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possible extent of resource use associated with alterna-
tive management options, feasibility, acceptability and
equity considerations. Recommendations and their
strength were decided by consensus and no recommen-
dation required voting based on the balance of all desir-
able and undesirable consequences. The panel agreed on
the final wording of recommendations and remarks with
further qualifications for each recommendation. The
final document including recommendations was
reviewed and approved by all members of the guideline
panel.
We labelled the recommendations as either “strong”
or “conditional” according to the GRADE approach. We
used the words “the panel members recommend” for
strong recommendations and “suggest” for conditional
recommendations. Table 1 provides the suggested inter-
pretation of strong and conditional recommendations by
patients, clinicians and health care policy makers.
Document review
A final draft document was reviewed by each member of
the guideline panel, finalized, approved, and submitted
to the WAO for peer review. The document was revised
to incorporate the pertinent comments suggested by the
external reviewers.
How to use these guidelines
The WAO GLAD-P guidelines about the use of prebi-
otics in the prevention of allergy in children are not
intended to impose a standard of care. They provide the
basis for rational decisions. Clinicians, patients, third-party
payers, institutional review committees, other stakeholders,
or the courts should never view these recommendations as
dictates. No recommendation can take into account all of
the often-compelling unique individual circumstances.
Therefore, no one charged with evaluating health care pro-
fessionals’ actions should attempt to apply the recommenda-
tions from these guidelines by rote or in a blanket fashion.
Statements about the underlying values and prefer-
ences, qualifying remarks and the evidence to decision
frameworks accompanying each recommendation are its
integral parts and serve to facilitate more accurate
interpretation. They should never be omitted when
quoting or translating recommendations from these
guidelines.
Recommendations
Question 1. Should prebiotics versus no prebiotics be
used in pregnant women?
Summary of the evidence
We found no systematic reviews, individual randomised
trials or observational studies that addressed this
question.
Conclusions and research needs
The guideline panel decided that under the current cir-
cumstances, they were not able to make an informed
judgment about the balance of potential desirable and
undesirable consequences of using prebiotic supple-
ments in pregnant women. The panel determined that
there is a need for well designed and executed random-
ized trial of prebiotic supplementation in pregnant
women that would measure development of allergy in
their children as well as other outcomes important in
this context. The panel identified the following add-
itional research questions: 1) is the effect of natural pre-
biotics in food different from that of supplements, 2) is
there an added benefit from prebiotic supplementation
on top of natural prebiotics, and 3) is there a differential
effect between the different types of prebiotics.
What others are saying
We found no other guidelines or position statements
that made specific recommendations about the use of
prebiotics in pregnant women.
Recommendation 1
The WAO guideline panel chose to provide no recom-
mendation at this time owing to lack of experimental
and observational studies in which prebiotic supple-
ments would be used in pregnant women.
Table 1 Interpretation of strong and conditional recommendations
Implications
for:
Strong recommendation Conditional recommendation
Patients Most individuals in this situation would want the recommended
course of action, and only a small proportion would not.
The majority of individuals in this situation would want the
suggested course of action, but many would not.
Clinicians Most individuals should receive the intervention. Adherence to
this recommendation according to the guideline could be used as
a quality criterion or performance indicator. Formal decision aids
are not likely to be needed to help individuals make decisions
consistent with their values and preferences.
Recognize that different choices will be appropriate for individual
patients and that you must help each patient arrive at a
management decision consistent with his or her values and
preferences. Decision aids may be useful in helping individuals to
make decisions consistent with their values and preferences.
Policy
makers
The recommendation can be adopted as policy in most situations. Policymaking will require substantial debate and involvement of
various stakeholders.
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Question 2. Should prebiotics versus no prebiotics be
used in breastfeeding mothers?
Summary of the evidence
We found no systematic reviews or individual rando-
mised trials or observational studies that addressed this
question.
Conclusions and research needs
Similarly to Question 1, the guideline panel decided that
under current circumstances they were not able to make
an informed judgment about the balance of potential de-
sirable and undesirable consequences of using prebiotic
supplements in breastfeeding mothers. The panel deter-
mined that there is a need for randomized trials of pre-
biotics in breastfeeding mothers. The additional
questions provided in the discussion of Question 1 re-
lated to the effects of natural prebiotics vs. their supple-
ments are equally relevant in the context of Question 2.
What others are saying
We found no other guidelines or position statements
that would make specific recommendations about the
use of prebiotics in breastfeeding mothers.
Recommendation 2
The WAO guideline panel chose to provide no recom-
mendation at this time owing to lack of experimental
and observational studies in which prebiotic supple-
ments would be used in breastfeeding mothers.
Question 3. Should prebiotics versus no prebiotics be
used in healthy infants?
Summary of the evidence
We found three systematic reviews [16–18] that ad-
dressed this question but only the review by Osborn
[18] assessed the use of prebiotics specifically for the
prevention of allergy in infants. We identified 15 add-
itional studies [19–33] published after the search for
the Osborn review was completed and studies that
measured other outcomes relevant in this context
(e.g., adverse effects of prebiotic supplementation).
Altogether, there were 18 randomized trials [19–36]
that addressed this question. All studies included in-
fants (from term newborns to 3 years of age) not be-
ing breastfed. Prebiotics were either added to a cereal
(two studies) [24, 28], used as an oral capsule (one
study), [29] or in milk formula (15 studies) [19–23,
25–27, 30–36]. Online Additional file 3 presents the
characteristics of all included studies.
Five studies reported the effect of prebiotic supplemen-
tation on development of eczema (either specifically
atopic eczema with positive skin tests, or any eczema),
[19, 25, 26, 34, 35] two studies reported development of
asthma or recurrent wheezing, [19, 25] one study [25]
assessed the risk of developing food allergy, and twelve
studies [20–24, 27, 29–31, 33, 34, 36] measured nutri-
tional status. No studies reported the risk of developing al-
lergic rhinitis or the composite outcome of “any allergy”.
Benefits
Prebiotic supplemented during the first year of life re-
duced the risk of developing asthma or recurrent wheez-
ing (RR: 0.37, 95 % CI: 0.17 to 0.80) and the risk of
developing food allergy (RR: 0.28, 95 % CI: 0.08 to 1.00).
Prebiotics also probably reduce the risk for developing
eczema in infants but the estimate is imprecise and con-
fidence interval does not exclude no effect (RR: 0.57,
95 % CI: 0.30 to 1.08). Studies assessing nutritional sta-
tus assessed as weight gain found no difference between
those receiving prebiotics and control groups (standard-
ized mean difference [SMD]: 0.06, 95 % CI: -0.02 to
0.15). Overall the certainty of these estimated effects is
very low owing to the serious risk of bias in the studies
and imprecision of the estimates (see evidence profile in
the online Additional file 4).
Harms and burden
Seven studies reported adverse effects [20, 22, 23, 28, 30,
32, 34] with a median risk of 34 % in the control groups.
All adverse effects were judged to be minor. The risk of
adverse effects was not different among those receiving
prebiotics and those receiving placebo (RR: 1.03, 95 %
CI: 0.93 to 1.14). The most commonly reported adverse
events were: rash, gastro-esophageal reflux, emesis, diar-
rhea, cramps, crying or “colic”. These events did not lead
to withdrawal from the studies. There is low certainty in
the estimate of the risk of adverse effects due to inad-
equate reporting in primary studies. However, given the
available evidence, the guideline panel considered the
risk of adverse effects most likely to be low.
Other decision criteria and considerations
Formulas supplemented with prebiotics should not be
considered a substitute for breast milk. All current
evidence concerns infants who were not breastfed,
thus, the availability of such formulas should not in-
fluence the decision to breastfeed and/or the duration
of breastfeeding.
Conclusions and research needs
The guideline panel determined that there is a low cer-
tainty of a net benefit from using prebiotics in infants.
Based on the body of available evidence, it is likely that
prebiotic supplementation in infants reduces the risk of
developing recurrent wheezing and possibly also the de-
velopment of food allergy. There is very low certainty that
there is an effect of prebiotics on other outcomes. How-
ever, because of low certainty of evidence or no published
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information about other outcomes, the fact that we did
not find the evidence of an effect on these outcomes does
not imply that such an effect does not exist.
The panel identified the following additional research
questions: 1) is the effect of natural prebiotics in food
different from that of supplementation, 2) is there an
added benefit from prebiotic supplementation in
addition to natural prebiotics, and 3) is there a differen-
tial effect between the different types of prebiotics. Fu-
ture research from rigorously designed and well-
executed randomized trials may have an important im-
pact on this recommendation.
What others are saying
The European Academy of Allergy and Clinical Immun-
ology (EAACI) Food Allergy and Anaphylaxis Guidelines
state that “there is no evidence to recommend prebiotics or
probiotics or other dietary supplements based on particular
nutrients to prevent food allergy.”[37]. The European
Society for Pediatric Gastroenterology, Hepatology, and
Nutrition (ESPGHAN) and North American Society for
Pediatric Gastroenterology, Hepatology, and Nutrition
(NASPGHAN) Committee on Nutrition consider that al-
though some benefits might be conferred to the administra-
tion of prebiotics in infant formulas, these results should
not influence practice until confirmed by additional studies.
They do not recommend routine administration of prebi-
otics for the prevention of allergies [38]. A guideline from
the Scottish Intercollegiate Guidelines Network (SIGN) for
the management of atopic eczema states that it is not pos-
sible to make recommendations for prebiotics to prevent
allergy based on the current evidence [39].
Recommendation 3
The WAO guideline panel suggests prebiotic supple-
mentation in not-exclusively breastfed infants, both at
high and at low risk for developing allergy (conditional
recommendation, low certainty of evidence).
The WAO guideline panel suggests that clinicians and
parents do not use prebiotic supplementation in exclu-
sively breastfed infants (conditional recommendation,
low certainty of the evidence).
Values and preferences
The recommendation to use prebiotics in not-
exclusively breastfed infants places a relatively higher
value on possible prevention of allergies and a relatively
lower value on additional cost of prebiotic supplementa-
tion. The recommendation to not use prebiotics in ex-
clusively breastfed infants places a relatively higher value
on avoiding additional cost and burden of implementa-
tion of such supplementation and a relatively lower
value on uncertain effect on prevention of allergies (cur-
rently there are also no studies of health effects of
prebiotics in exclusively breastfed infants and the panel
found it not justified to extrapolate from the effects ob-
served in non-exclusively breastfed infants).
Explanations and other considerations
These recommendations should not lead to any change
in the practice or promotion of breastfeeding of infants.
Formulas supplemented with prebiotics should not be
considered a substitute for breast milk. Sole availability
of such formulas should not influence the decision to
breastfeed and/or the duration of breastfeeding. These
recommendations apply to otherwise healthy infants in
whom prebiotics would be used with the goal of pre-
venting allergies. See the evidence to recommendation
table in online Additional file 5.
Priorities for revision of the guidelines
Plans for updating these guidelines
Guidelines are living documents. To remain useful, they
need to be updated regularly as new information accu-
mulates. A revision of this document will be needed, be-
cause there was limited evidence for many clinical
questions. This document will be updated when major
new research is published. The need for update will be
determined not later than in 2019.
Updating or adapting recommendations locally
The methods used to develop these guidelines are
transparent. The recommendations have been devel-
oped to be as specific and detailed as possible with-
out losing sight of the simplicity of the document.
Since GLAD-P are meant as international guidelines,
the guideline panel encourages feedback on all its as-
pects including their applicability in individual coun-
tries. This feedback will be considered when revising
the document.
Adaptation of these guidelines will be necessary in
many circumstances. Depending on when such a process
takes place, the following steps should be taken:
▪ Appointing a guideline committee comprising
clinicians and methodologists
▪ Determining the scope of the local guidelines
▪ Defining the relevant clinical questions to be
addressed in local guidelines
▪ Reviewing and updating the evidence profiles and
evidence-to-decision frameworks if necessary
▪ Reviewing the recommendations in the GLAD-P
guidelines (the recommendations may need to be modi-
fied at a local level, depending on the local values and
preferences, availability of medications, costs, etc.)
▪ Disseminating the guidelines, with a clear “use by” date
▪ Developing a method to obtain feedback and plans for
review and update.
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Priorities for research
During the guideline development process we identified
a need for more data on specific topics. This resulted in
the following recommendations for research. We
summarize these gaps in the evidence as research rec-
ommendations, to assist those in a position to provide
such information through the design and execution of
specific research projects.
Specific research needs to be addressed:
1. Development of instruments for evaluating the risk
of allergy in children (the family history predicts
only about 30 % of the population risk).
2. Evaluation of effects of using prebiotics in
breastfeeding mothers.
3. Evaluation of effects of using prebiotics in pregnant
women.
4. Evaluation of the effects of different ways of
administration of prebiotics, e.g. as milk hydrolysed
formula, dairy supplements, stand-alone supple-
ments, etc.
5. Performance of rigorously designed, adequately
powered, and well-executed randomized trials of the
different prebiotics (e.g., GOS vs. FOS) with well-
defined patient important outcomes.
6. The impact of sub-groups in the effect (if any) of
prebiotics on the prevention of allergies, such as:
a. Infants at high vs. low risk of allergies
b. Those being exclusively breastfed vs. not
exclusively breastfed
c. Those born by caesarean-section vs. those born
by vaginal delivery
7. Large observational studies might be the only design
feasible for detecting rare adverse events
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